{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T10:43:48Z","timestamp":1768733028292,"version":"3.49.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgme.2024.108561","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T16:18:52Z","timestamp":1722701932000},"page":"108561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey"],"prefix":"10.1016","volume":"143","author":[{"given":"Albina","family":"Nowak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaco","family":"Botha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Anagnostopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2024.108561_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108561_bb0010","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.2147\/DDDT.S313789","article-title":"Prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a Fabry Outcome Survey analysis","volume":"15","author":"Hughes","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2024.108561_bb0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2024.108561_bb0020","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.2147\/DDDT.S207856","article-title":"Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey (FOS) analysis","volume":"13","author":"Ramaswami","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2024.108561_bb0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymgme.2024.108561_bb0030","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2024.108561_bb0035","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2024.108561_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2016.05.009","article-title":"Fabry in the older patient: clinical consequences and possibilities for treatment","volume":"118","author":"Lidove","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108561_bb0045","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2024.108561_bb0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108561_bb0055","series-title":"Elfabrio Summary of Product Information","author":"European Medicines Agency","year":"2023"},{"key":"10.1016\/j.ymgme.2024.108561_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2024.108561_bb0065","first-page":"21","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2024.108561_bb0070","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","article-title":"Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease","volume":"38","author":"Fellgiebel","year":"2014","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.ymgme.2024.108561_bb0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2024.108561_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108561_bb0085","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2024.108561_bb0090","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2024.108561_bb0095","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2024.108561_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.ymgme.2024.108561_bb0105","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.clinthera.2020.10.007","article-title":"Effects of baseline left ventricular hypertrophy and decreased renal function on cardiovascular and renal outcomes in patients with Fabry disease treated with agalsidase alfa: a Fabry Outcome Survey study","volume":"42","author":"Feriozzi","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2024.108561_bb0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108561_bb0115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/HCO.0000000000000308","article-title":"Fabry disease: will markers of early disease enable early treatment and better outcomes?","volume":"31","author":"Hughes","year":"2016","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.ymgme.2024.108561_bb0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000448968","article-title":"Long term treatment with enzyme replacement therapy in patients with Fabry disease","volume":"134","author":"Oder","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.ymgme.2024.108561_bb0125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108561_bb0130","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/DDDT.S249433","article-title":"Analysis of renal and cardiac outcomes in male participants in the Fabry Outcome Survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age","volume":"14","author":"Parini","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2024.108561_bb0135","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2024.108561_bb0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108561_bb0145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2024.108561_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12914","article-title":"Time delays in the diagnosis and treatment of Fabry disease","volume":"71","author":"Reisin","year":"2017","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ymgme.2024.108561_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035182","article-title":"Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative","volume":"10","author":"Hughes","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymgme.2024.108561_bb0160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2024.108561_bb0165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13023-022-02392-9","article-title":"Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry","volume":"17","author":"Beck","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108561_bb0170","series-title":"Fabry Disease","author":"Elstein","year":"2010"},{"key":"10.1016\/j.ymgme.2024.108561_bb0175","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2024.108561_bb0180","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup","volume":"57","author":"Germain","year":"2020","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108561_bb0185","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ene.13775","article-title":"Genomic screening of Fabry disease in young stroke patients: the Taiwan experience and a review of the literature","volume":"26","author":"Lee","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2024.108561_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase A mutations as a basis for a new classification system in Fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymgme.2024.108561_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596420","article-title":"Screening for Fabry disease in young strokes in the Australian Stroke Clinical Registry (AuSCR)","volume":"11","author":"Malavera","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymgme.2024.108561_bb0200","first-page":"107","article-title":"The clinical profiles of female patients with Fabry disease in Latin America: a Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status","volume":"49","author":"Martins","year":"2019","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108561_bb0205","first-page":"82","article-title":"Fabry disease in India: a multicenter study of the clinical and mutation spectrum in 54 patients","volume":"56","author":"Nampoothiri","year":"2020","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108561_bb0210","article-title":"Ventricular tachycardia: a presentation of Fabry disease case report","volume":"3","author":"Pavlu","year":"2019","journal-title":"Eur. Heart J. Case Rep."},{"key":"10.1016\/j.ymgme.2024.108561_bb0215","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.3390\/jcm10163543","article-title":"Detailed phenotype of GLA variants identified by the nationwide neurological screening of stroke patients in the Czech Republic","volume":"10","author":"Rekova","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2024.108561_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1502","article-title":"Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening","volume":"8","author":"Sawada","year":"2020","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.ymgme.2024.108561_bb0225","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2174\/1871530320666200708135826","article-title":"Genetic management algorithm in high-risk Fabry disease cases; especially in female indexes with mutations","volume":"21","author":"Sezer","year":"2021","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"10.1016\/j.ymgme.2024.108561_bb0230","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","article-title":"Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations","volume":"2","author":"Shabbeer","year":"2006","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.ymgme.2024.108561_bb0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clinbiochem.2020.12.002","article-title":"Lysosomal storage disorders: novel and frequent pathogenic variants in a large cohort of Indian patients of Pompe, Fabry, Gaucher and Hurler disease","volume":"89","author":"Thomas","year":"2021","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgme.2024.108561_bb0240","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/jhg.2011.31","article-title":"Fabry-database.org: database of the clinical phenotypes, genotypes and mutant alpha-galactosidase A structures in Fabry disease","volume":"56","author":"Saito","year":"2011","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2024.108561_bb0245","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ymgme.2016.11.082","article-title":"The Fabry disease genotype-phenotype database (dbFGP): an international expert consortium","volume":"120","author":"Desnick","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108561_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ymgme.2024.108561_bb0255","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ymgme.2024.108561_bb0260","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson\u2013Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2024.108561_bb0265","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ehf2.12687","article-title":"Age-related longitudinal change in cardiac structure and function in adults at increased cardiovascular risk","volume":"7","author":"Gong","year":"2020","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ymgme.2024.108561_bb0270","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40620-014-0077-9","article-title":"A longitudinal assessment of the natural rate of decline in renal function with age","volume":"27","author":"Cohen","year":"2014","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ymgme.2024.108561_bb0275","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1111\/jgs.18046","article-title":"Age-adapted eGFR thresholds underestimate the risks beyond kidney failure associated with CKD in older populations","volume":"70","author":"Lees","year":"2022","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ymgme.2024.108561_bb0280","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","article-title":"Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study","volume":"34","author":"Madsen","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2024.108561_bb0285","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2024.108561_bb0290","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:20:31Z","timestamp":1742437231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224004451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":58,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1096719224004451"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108561","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Takeda Pharmaceuticals International AG. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108561"}}